Published in Cancer Res on February 01, 2005
Latent bone metastasis in breast cancer tied to Src-dependent survival signals. Cancer Cell (2009) 5.24
Prostaglandins and cancer. Gut (2005) 3.44
CXCL12 / CXCR4 / CXCR7 chemokine axis and cancer progression. Cancer Metastasis Rev (2010) 3.24
Regulation of CXCR4 signaling. Biochim Biophys Acta (2006) 3.16
Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol (2015) 2.44
Organ selectivity in metastasis: regulation by chemokines and their receptors. Clin Exp Metastasis (2007) 2.18
CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun (2007) 1.96
The role of HER2 in cancer therapy and targeted drug delivery. J Control Release (2010) 1.88
The orphan tyrosine kinase receptor, ROR2, mediates Wnt5A signaling in metastatic melanoma. Oncogene (2009) 1.75
Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol (2009) 1.75
Chemokines in health and disease. Exp Cell Res (2011) 1.69
Mouse models of breast cancer metastasis. Breast Cancer Res (2006) 1.62
The novel role of the mu opioid receptor in lung cancer progression: a laboratory investigation. Anesth Analg (2010) 1.46
A synthetic biology approach reveals a CXCR4-G13-Rho signaling axis driving transendothelial migration of metastatic breast cancer cells. Sci Signal (2011) 1.45
The Role of chemokine receptor CXCR4 in breast cancer metastasis. Am J Cancer Res (2013) 1.44
ITF2 is a target of CXCR4 in MDA-MB-231 breast cancer cells and is associated with reduced survival in estrogen receptor-negative breast cancer. Cancer Biol Ther (2010) 1.44
Molecular imaging of CXCR4 receptor expression in human cancer xenografts with [64Cu]AMD3100 positron emission tomography. Cancer Res (2010) 1.32
Small molecule inhibitors of CXCR4. Theranostics (2013) 1.30
Blockade of SDF-1/CXCR4 signalling inhibits pancreatic cancer progression in vitro via inactivation of canonical Wnt pathway. Br J Cancer (2008) 1.26
CXCL12/CXCR4 transactivates HER2 in lipid rafts of prostate cancer cells and promotes growth of metastatic deposits in bone. Mol Cancer Res (2008) 1.23
Delivery systems for the direct application of siRNAs to induce RNA interference (RNAi) in vivo. J Biomed Biotechnol (2006) 1.21
PTHrP drives breast tumor initiation, progression, and metastasis in mice and is a potential therapy target. J Clin Invest (2011) 1.17
Targeting CXCL12/CXCR4 signaling with oncolytic virotherapy disrupts tumor vasculature and inhibits breast cancer metastases. Proc Natl Acad Sci U S A (2013) 1.17
Chemokine receptors in advanced breast cancer: differential expression in metastatic disease sites with diagnostic and therapeutic implications. Ann Oncol (2009) 1.12
Expression of CXCR4 and breast cancer prognosis: a systematic review and meta-analysis. BMC Cancer (2014) 1.11
Imaging CXCR4 expression in human cancer xenografts: evaluation of monocyclam 64Cu-AMD3465. J Nucl Med (2011) 1.11
Role of hypoxia-inducible factors in breast cancer metastasis. Future Oncol (2013) 1.09
Advances in microRNAs: implications for gene therapists. Hum Gene Ther (2008) 1.08
Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. J Med Chem (2010) 1.08
Interaction between CXCR4 and CCL20 pathways regulates tumor growth. PLoS One (2009) 1.07
The intricate role of CXCR4 in cancer. Adv Cancer Res (2014) 1.04
Modulatory effects of heparin and short-length oligosaccharides of heparin on the metastasis and growth of LMD MDA-MB 231 breast cancer cells in vivo. Br J Cancer (2007) 1.03
Chemokine signaling in cancer: Implications on the tumor microenvironment and therapeutic targeting. Cancer Ther (2009) 1.03
Inhibition of breast cancer cell invasion by melatonin is mediated through regulation of the p38 mitogen-activated protein kinase signaling pathway. Breast Cancer Res (2010) 1.03
Reassessment of CXCR4 chemokine receptor expression in human normal and neoplastic tissues using the novel rabbit monoclonal antibody UMB-2. PLoS One (2008) 1.01
Multiple functions of CXCL12 in a syngeneic model of breast cancer. Mol Cancer (2010) 1.00
Signal transducers and activators of transcription-3 up-regulates tissue inhibitor of metalloproteinase-1 expression and decreases invasiveness of breast cancer. Am J Pathol (2006) 0.99
Concepts in in vivo siRNA delivery for cancer therapy. J Cell Physiol (2009) 0.98
Targeting polymer therapeutics to bone. Adv Drug Deliv Rev (2012) 0.98
Loss of interferon regulatory factor 5 (IRF5) expression in human ductal carcinoma correlates with disease stage and contributes to metastasis. Breast Cancer Res (2011) 0.97
The CXCR4-SDF1alpha axis is a critical mediator of rhabdomyosarcoma metastatic signaling induced by bone marrow stroma. Clin Exp Metastasis (2007) 0.95
Silencing the hsp25 gene eliminates migration capability of the highly metastatic murine 4T1 breast adenocarcinoma cell. Tumour Biol (2005) 0.95
Targeting of the Akt-nuclear factor-kappa B signaling network by [1-(4-chloro-3-nitrobenzenesulfonyl)-1H-indol-3-yl]-methanol (OSU-A9), a novel indole-3-carbinol derivative, in a mouse model of hepatocellular carcinoma. Mol Pharmacol (2009) 0.94
Novel anti-metastatic action of cidofovir mediated by inhibition of E6/E7, CXCR4 and Rho/ROCK signaling in HPV tumor cells. PLoS One (2009) 0.94
Dual-function CXCR4 antagonist polyplexes to deliver gene therapy and inhibit cancer cell invasion. Angew Chem Int Ed Engl (2012) 0.94
Chemokines: key players in cancer progression and metastasis. Front Biosci (Schol Ed) (2011) 0.94
Nuclear localization of CXCR4 determines prognosis for colorectal cancer patients. Cancer Microenviron (2008) 0.92
Post-transcriptional regulation of chemokine receptor CXCR4 by estrogen in HER2 overexpressing, estrogen receptor-positive breast cancer cells. Breast Cancer Res Treat (2008) 0.91
CXCR4 drives the metastatic phenotype in breast cancer through induction of CXCR2 and activation of MEK and PI3K pathways. Mol Biol Cell (2014) 0.90
AMD3465, a novel CXCR4 receptor antagonist, abrogates schistosomal antigen-elicited (type-2) pulmonary granuloma formation. Am J Pathol (2006) 0.90
Targeting CXCR4 with cell-penetrating pepducins in lymphoma and lymphocytic leukemia. Blood (2011) 0.90
Adhesion molecules and chemokines: the navigation system for circulating tumor (stem) cells to metastasize in an organ-specific manner. Clin Exp Metastasis (2007) 0.90
C-X-C motif chemokine 12/C-X-C chemokine receptor type 7 signaling regulates breast cancer growth and metastasis by modulating the tumor microenvironment. Breast Cancer Res (2014) 0.90
Chemokine receptor CXCR4 as a therapeutic target for neuroectodermal tumors. Semin Cancer Biol (2008) 0.90
Chemokines, costimulatory molecules and fusion proteins for the immunotherapy of solid tumors. Immunotherapy (2011) 0.89
Cure of metastatic growth of EMT6 tumor cells in mice following manipulation of CD200:CD200R signaling. Breast Cancer Res Treat (2013) 0.89
Effect of biodegradability on CXCR4 antagonism, transfection efficacy and antimetastatic activity of polymeric Plerixafor. Biomaterials (2014) 0.88
Nanoscale obstacle arrays frustrate transport of EphA2-Ephrin-A1 clusters in cancer cell lines. Nano Lett (2013) 0.88
Plasma malondialdehyde levels and CXCR4 expression in peripheral blood cells of breast cancer patients. J Cancer Res Clin Oncol (2009) 0.88
Regulation of cell migration by sphingomyelin synthases: sphingomyelin in lipid rafts decreases responsiveness to signaling by the CXCL12/CXCR4 pathway. Mol Cell Biol (2012) 0.87
Interplay of genes regulated by estrogen and diindolylmethane in breast cancer cell lines. Mol Med (2007) 0.87
Proteomic profiling identifies breast tumor metastasis-associated factors in an isogenic model. Proteomics (2007) 0.87
The decreased metastatic potential of rhabdomyosarcoma cells obtained through MET receptor downregulation and the induction of differentiation. Cell Death Dis (2013) 0.86
Effects of CXCR4 siRNA/dextran-spermine nanoparticles on CXCR4 expression and serum LDH levels in a mouse model of colorectal cancer metastasis to the liver. Cancer Manag Res (2011) 0.86
Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors. ChemMedChem (2013) 0.85
Downregulation of the CXCR4 receptor inhibits cervical carcinoma metastatic behavior in vitro and in vivo. Int J Oncol (2014) 0.85
Downregulation of steroid receptor coactivator-2 modulates estrogen-responsive genes and stimulates proliferation of mcf-7 breast cancer cells. PLoS One (2013) 0.85
CXCR4 in Cancer and Its Regulation by PPARgamma. PPAR Res (2008) 0.85
Integrating structure to protein-protein interaction networks that drive metastasis to brain and lung in breast cancer. PLoS One (2013) 0.85
Identification and transcript analysis of a novel wallaby (Macropus eugenii) basal-like breast cancer cell line. Mol Cancer (2008) 0.84
Cancer stem cells and side population cells in breast cancer and metastasis. Cancers (Basel) (2011) 0.84
MALDI-Mass Spectrometric Imaging Revealing Hypoxia-Driven Lipids and Proteins in a Breast Tumor Model. Anal Chem (2015) 0.83
Examination of structure-activity relationship of viologen-based dendrimers as CXCR4 antagonists and gene carriers. Bioconjug Chem (2014) 0.83
RNAi targeting CXCR4 inhibits proliferation and invasion of esophageal carcinoma cells. Diagn Pathol (2013) 0.83
Biological functions of decorin in cancer. Chin J Cancer (2013) 0.83
Molecular alterations that drive breast cancer metastasis to bone. Bonekey Rep (2015) 0.83
Optimal management of bone metastases in breast cancer patients. Breast Cancer (Dove Med Press) (2011) 0.83
Posttranscriptional control of the chemokine receptor CXCR4 expression in cancer cells. Carcinogenesis (2014) 0.82
Inhibitory effect of HGF on invasiveness of aggressive MDA-MB231 breast carcinoma cells, and role of HDACs. Br J Cancer (2008) 0.82
Dia-interacting protein (DIP) imposes migratory plasticity in mDia2-dependent tumor cells in three-dimensional matrices. PLoS One (2012) 0.82
In vivo efficacy and off-target effects of locked nucleic acid (LNA) and unlocked nucleic acid (UNA) modified siRNA and small internally segmented interfering RNA (sisiRNA) in mice bearing human tumor xenografts. Artif DNA PNA XNA (2010) 0.82
CXCR4 suppression attenuates EGFRvIII-mediated invasion and induces p38 MAPK-dependent protein trafficking and degradation of EGFRvIII in breast cancer cells. Cancer Lett (2011) 0.82
Discovery and computer aided potency optimization of a novel class of small molecule CXCR4 antagonists. PLoS One (2013) 0.81
Intracellular CXCR4⁺ cell targeting with T22-empowered protein-only nanoparticles. Int J Nanomedicine (2012) 0.81
The CXCL12/CXCR4 autocrine loop increases the metastatic potential of non-small cell lung cancer in vitro. Oncol Lett (2012) 0.81
Inhibition of breast cancer metastasis with microRNA-302a by downregulation of CXCR4 expression. Breast Cancer Res Treat (2014) 0.80
BreastDefend™ prevents breast-to-lung cancer metastases in an orthotopic animal model of triple-negative human breast cancer. Oncol Rep (2012) 0.80
Cationized dextran nanoparticle-encapsulated CXCR4-siRNA enhanced correlation between CXCR4 expression and serum alkaline phosphatase in a mouse model of colorectal cancer. Int J Nanomedicine (2012) 0.79
Comparison of immunity in mice cured of primary/metastatic growth of EMT6 or 4THM breast cancer by chemotherapy or immunotherapy. PLoS One (2014) 0.79
Immunohistochemical expression of CXCR4 on breast cancer and its clinical significance. Anal Cell Pathol (Amst) (2015) 0.79
GLI1 orchestrates CXCR4/CXCR7 signaling to enhance migration and metastasis of breast cancer cells. Oncotarget (2015) 0.79
Inhibition of chemokine receptor expression on uveal melanomas by CXCR4 siRNA and its effect on uveal melanoma liver metastases. Invest Ophthalmol Vis Sci (2009) 0.79
Downregulation of microRNA-206 promotes invasion and angiogenesis of triple negative breast cancer. Biochem Biophys Res Commun (2016) 0.78
Retracted siRNA-participated chemotherapy: an efficient and specific therapeutic against gastric cancer. J Cancer Res Clin Oncol (2013) 0.78
The influence of lentivirus-mediated CXCR4 RNA interference on hepatic metastasis of colorectal cancer. Int J Oncol (2014) 0.78
Krüppel-like factor 8 activates the transcription of C-X-C cytokine receptor type 4 to promote breast cancer cell invasion, transendothelial migration and metastasis. Oncotarget (2016) 0.77
Secondary lymphoid organ homing phenotype of human myeloid dendritic cells disrupted by an intracellular oral pathogen. Infect Immun (2013) 0.77
Targeting chemokine receptor CXCR4 for treatment of HIV-1 infection, tumor progression, and metastasis. Curr Top Med Chem (2014) 0.77
Practical method for radioactivity distribution analysis in small-animal PET cancer studies. Appl Radiat Isot (2008) 0.77
SDF-1alpha concentration dependent modulation of RhoA and Rac1 modifies breast cancer and stromal cells interaction. BMC Cancer (2015) 0.77
Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans. Nature (1998) 72.56
Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature (2001) 57.23
Involvement of chemokine receptors in breast cancer metastasis. Nature (2001) 26.07
A species of small antisense RNA in posttranscriptional gene silencing in plants. Science (1999) 19.34
Functional anatomy of siRNAs for mediating efficient RNAi in Drosophila melanogaster embryo lysate. EMBO J (2001) 12.88
RNA interference--2001. Genes Dev (2001) 7.68
RNA interference targeting Fas protects mice from fulminant hepatitis. Nat Med (2003) 7.37
Analysis of gene function in somatic mammalian cells using small interfering RNAs. Methods (2002) 6.67
Efficient stereospecific synthesis of no-carrier-added 2-[18F]-fluoro-2-deoxy-D-glucose using aminopolyether supported nucleophilic substitution. J Nucl Med (1986) 4.69
RNA silencing: the genome's immune system. Science (2002) 3.66
Chemokine receptor inhibition by AMD3100 is strictly confined to CXCR4. FEBS Lett (2002) 3.56
Gene silencing by systemic delivery of synthetic siRNAs in adult mice. J Mol Biol (2003) 3.27
Efficient delivery of siRNA for inhibition of gene expression in postnatal mice. Nat Genet (2002) 3.08
A small interfering RNA targeting vascular endothelial growth factor as cancer therapeutics. Cancer Res (2004) 2.72
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res (2004) 2.31
Suppression of chemokine receptor expression by RNA interference allows for inhibition of HIV-1 replication. AIDS (2002) 2.29
Focal FDG uptake in mediastinal brown fat mimicking malignancy: a potential pitfall resolved on PET/CT. AJR Am J Roentgenol (2004) 2.06
T140 analogs as CXCR4 antagonists identified as anti-metastatic agents in the treatment of breast cancer. FEBS Lett (2003) 1.71
Down-regulation of CXCR4 by inducible small interfering RNA inhibits breast cancer cell invasion in vitro. Cancer Res (2003) 1.60
Potent suppression of HIV type 1 infection by a short hairpin anti-CXCR4 siRNA. AIDS Res Hum Retroviruses (2003) 1.23
Enhanced gene silencing by the application of multiple specific small interfering RNAs. FEBS Lett (2003) 1.05
Initial experience with the radiotracer anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid with PET/CT in prostate carcinoma. J Nucl Med (2007) 2.83
Inhibition of breast cancer metastasis by selective synthetic polypeptide against CXCR4. Cancer Res (2004) 2.31
CXCR4/CXCL12 axis promotes VEGF-mediated tumor angiogenesis through Akt signaling pathway. Biochem Biophys Res Commun (2007) 1.96
Involvement of miR-326 in chemotherapy resistance of breast cancer through modulating expression of multidrug resistance-associated protein 1. Biochem Pharmacol (2009) 1.75
Role of the SDF-1/CXCR4 axis in the pathogenesis of lung injury and fibrosis. Am J Respir Cell Mol Biol (2007) 1.61
(18)F-FECNT: validation as PET dopamine transporter ligand in parkinsonism. Exp Neurol (2010) 1.61
The absence of LPA2 attenuates tumor formation in an experimental model of colitis-associated cancer. Gastroenterology (2009) 1.56
Assessment and treatment of elopement: a replication and extension. J Appl Behav Anal (2003) 1.49
Dopaminergic mechanisms of reduced basal ganglia responses to hedonic reward during interferon alfa administration. Arch Gen Psychiatry (2012) 1.48
LPA2 receptor mediates mitogenic signals in human colon cancer cells. Am J Physiol Cell Physiol (2005) 1.47
Cells of the osteoclast lineage as mediators of the anabolic actions of parathyroid hormone in bone. Endocrinology (2005) 1.44
Blockade of invasion and metastasis of breast cancer cells via targeting CXCR4 with an artificial microRNA. Biochem Biophys Res Commun (2007) 1.40
Vasculostatin inhibits intracranial glioma growth and negatively regulates in vivo angiogenesis through a CD36-dependent mechanism. Cancer Res (2009) 1.39
CXC chemokine receptor-4 antagonist blocks both growth of primary tumor and metastasis of head and neck cancer in xenograft mouse models. Cancer Res (2007) 1.38
Effects of combined dopamine and serotonin transporter inhibitors on cocaine self-administration in rhesus monkeys. J Pharmacol Exp Ther (2006) 1.34
Detection of recurrent prostate carcinoma with anti-1-amino-3-18F-fluorocyclobutane-1-carboxylic acid PET/CT and 111In-capromab pendetide SPECT/CT. Radiology (2011) 1.30
A preliminary study of anti-1-amino-3-18F-fluorocyclobutyl-1-carboxylic acid for the detection of prostate cancer. J Nucl Med (2007) 1.29
Lysophosphatidic acid facilitates proliferation of colon cancer cells via induction of Krüppel-like factor 5. J Biol Chem (2007) 1.29
Effects of dopamine transporter inhibitors on cocaine self-administration in rhesus monkeys: relationship to transporter occupancy determined by positron emission tomography neuroimaging. J Pharmacol Exp Ther (2004) 1.24
Antitumor effect of 2-methoxyestradiol in a rat orthotopic brain tumor model. Cancer Res (2006) 1.23
Metabolic positron emission tomography imaging in cancer detection and therapy response. Semin Oncol (2011) 1.21
Characterization of primary prostate carcinoma by anti-1-amino-2-[(18)F] -fluorocyclobutane-1-carboxylic acid (anti-3-[(18)F] FACBC) uptake. Am J Nucl Med Mol Imaging (2013) 1.21
Development of a unique small molecule modulator of CXCR4. PLoS One (2012) 1.18
Relationship between rate of drug uptake in brain and behavioral pharmacology of monoamine transporter inhibitors in rhesus monkeys. Pharmacol Biochem Behav (2008) 1.17
Targeting tissue factor-expressing tumor angiogenesis and tumors with EF24 conjugated to factor VIIa. J Drug Target (2008) 1.17
Regulation of miR-19 to breast cancer chemoresistance through targeting PTEN. Pharm Res (2011) 1.16
Lower expression of CXCR4 in lymph node metastases than in primary breast cancers: potential regulation by ligand-dependent degradation and HIF-1alpha. Biochem Biophys Res Commun (2006) 1.15
Initial human PET imaging studies with the dopamine transporter ligand 18F-FECNT. J Nucl Med (2003) 1.13
Discovery of small molecule CXCR4 antagonists. J Med Chem (2007) 1.12
Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis. Appl Radiat Isot (2003) 1.11
Biodistribution and radiation dosimetry of the synthetic nonmetabolized amino acid analogue anti-18F-FACBC in humans. J Nucl Med (2007) 1.11
Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity. J Med Chem (2010) 1.08
Predictors of remission in depression to individual and combined treatments (PReDICT): study protocol for a randomized controlled trial. Trials (2012) 1.06
MicroRNA-302 replacement therapy sensitizes breast cancer cells to ionizing radiation. Pharm Res (2012) 1.05
Radiohalogenated nonnatural amino acids as PET and SPECT tumor imaging agents. Med Res Rev (2011) 1.03
Increases in NMR-visible lipid and glycerophosphocholine during phenylbutyrate-induced apoptosis in human prostate cancer cells. Biochim Biophys Acta (2005) 1.03
Measurement of dopamine transporter occupancy for multiple injections of cocaine using a single injection of [F-18]FECNT. Synapse (2002) 1.02
MR-based attenuation correction for hybrid PET-MR brain imaging systems using deformable image registration. Med Phys (2010) 1.02
Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells. Nucl Med Biol (2011) 1.01
Interaction of cocaine and dopamine transporter inhibitors on behavior and neurochemistry in monkeys. Pharmacol Biochem Behav (2005) 1.00
Non-natural amino acids for tumor imaging using positron emission tomography and single photon emission computed tomography. Cancer Metastasis Rev (2008) 0.99
Cortical activation during cocaine use and extinction in rhesus monkeys. Psychopharmacology (Berl) (2009) 0.99
Dietary intake of soy genistein is associated with lung function in patients with asthma. J Asthma (2004) 0.98
In vivo comparison of the reinforcing and dopamine transporter effects of local anesthetics in rhesus monkeys. Synapse (2005) 0.98
Inhibition of the NF-κB signaling pathway by the curcumin analog, 3,5-Bis(2-pyridinylmethylidene)-4-piperidone (EF31): anti-inflammatory and anti-cancer properties. Int Immunopharmacol (2011) 0.98
Arylsulfonamide KCN1 inhibits in vivo glioma growth and interferes with HIF signaling by disrupting HIF-1α interaction with cofactors p300/CBP. Clin Cancer Res (2012) 0.97
Lysophosphatidic acid prevents apoptosis of Caco-2 colon cancer cells via activation of mitogen-activated protein kinase and phosphorylation of Bad. Biochim Biophys Acta (2007) 0.97
Regulation of hypoxia-inducible factor 1α (HIF-1α) by lysophosphatidic acid is dependent on interplay between p53 and Krüppel-like factor 5. J Biol Chem (2013) 0.97
The absence of LPA receptor 2 reduces the tumorigenesis by ApcMin mutation in the intestine. Am J Physiol Gastrointest Liver Physiol (2010) 0.97
Inflammation is related to coronary flow reserve detected by positron emission tomography in asymptomatic male twins. J Am Coll Cardiol (2011) 0.96
MAGI-3 competes with NHERF-2 to negatively regulate LPA2 receptor signaling in colon cancer cells. Gastroenterology (2010) 0.95
Major depression and coronary flow reserve detected by positron emission tomography. Arch Intern Med (2009) 0.93
Synthesis and in vivo evaluation of fluorine-18 and iodine-123 labeled 2beta-carbo(2-fluoroethoxy)-3beta-(4'-((Z)-2-iodoethenyl)phenyl)nortropane as a candidate serotonin transporter imaging agent. J Med Chem (2007) 0.93
Magnetic resonance spectroscopic imaging of tumor metabolic markers for cancer diagnosis, metabolic phenotyping, and characterization of tumor microenvironment. Dis Markers (2004) 0.93
Chronic interferon-α decreases dopamine 2 receptor binding and striatal dopamine release in association with anhedonia-like behavior in nonhuman primates. Neuropsychopharmacology (2013) 0.93
Inhibition of the CXCL12/CXCR4-axis as preventive therapy for radiation-induced pulmonary fibrosis. PLoS One (2013) 0.92
Attenuation of obliterative bronchiolitis by a CXCR4 antagonist in the murine heterotopic tracheal transplant model. J Heart Lung Transplant (2008) 0.91
Synthesis and evaluation of C-11, F-18 and I-125 small molecule radioligands for detecting oxytocin receptors. Bioorg Med Chem (2012) 0.91
Radiolabeled amino acids for tumor imaging with PET: radiosynthesis and biological evaluation of 2-amino-3-[18F]fluoro-2-methylpropanoic acid and 3-[18F]fluoro-2-methyl-2-(methylamino)propanoic acid. J Med Chem (2002) 0.90
Role of dopamine transporters in the behavioral effects of 3,4-methylenedioxymethamphetamine (MDMA) in nonhuman primates. Psychopharmacology (Berl) (2009) 0.90
Neurobiological changes mediating the effects of chronic fluoxetine on cocaine use. Neuropsychopharmacology (2012) 0.90
Semi-automated preparation of the dopamine transporter ligand [(18)F]FECNT for human PET imaging studies. Appl Radiat Isot (2005) 0.90
Comparative evaluation of transport mechanisms of trans-1-amino-3-[¹⁸F]fluorocyclobutanecarboxylic acid and L-[methyl-¹¹C]methionine in human glioma cell lines. Brain Res (2013) 0.90
The immunophilin ligand GPI1046 protects neurons from the lethal effects of the HIV-1 proteins gp120 and Tat by modulating endoplasmic reticulum calcium load. J Neurochem (2006) 0.89
Functional brain imaging alterations in acne patients treated with isotretinoin. Am J Psychiatry (2005) 0.89
Synthesis of syn- and anti-1-amino-3-[18F]fluoromethyl-cyclobutane-1-carboxylic acid (FMACBC), potential PET ligands for tumor detection. J Med Chem (2002) 0.89
Design and in vitro activities of N-alkyl-N-[(8-R-2,2-dimethyl-2H-chromen-6-yl)methyl]heteroarylsulfonamides, novel, small-molecule hypoxia inducible factor-1 pathway inhibitors and anticancer agents. J Med Chem (2012) 0.89
Facile stereospecific synthesis and biological evaluation of (S)- and (R)-2-amino-2-methyl-4-[123I]iodo-3-(E)-butenoic acid for brain tumor imaging with single photon emission computerized tomography. J Med Chem (2007) 0.88
Cancer scene investigation: how a cold virus became a tumor killer. Future Oncol (2005) 0.88
Decreased brainstem and putamen SERT binding potential in depressed suicide attempters using [11C]-zient PET imaging. Depress Anxiety (2013) 0.87
Early prediction of response to Vorinostat in an orthotopic rat glioma model. NMR Biomed (2012) 0.87
Differences in transport mechanisms of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid in inflammation, prostate cancer, and glioma cells: comparison with L-[methyl-11C]methionine and 2-deoxy-2-[18F]fluoro-D-glucose. Mol Imaging Biol (2014) 0.87
Kinetic analyses of trans-1-amino-3-[18F]fluorocyclobutanecarboxylic acid transport in Xenopus laevis oocytes expressing human ASCT2 and SNAT2. Nucl Med Biol (2013) 0.87
Growth and Tolerance of Preterm Infants Fed a New Extensively Hydrolyzed Liquid Human Milk Fortifier. J Pediatr Gastroenterol Nutr (2015) 0.86
Isoflurane alters the amount of dopamine transporter expressed on the plasma membrane in humans. Anesthesiology (2004) 0.86
Benzenesulfonamides: a unique class of chemokine receptor type 4 inhibitors. ChemMedChem (2013) 0.85
Synthesis and in vivo evaluation of halogenated N,N-dimethyl-2-(2'-amino-4'-hydroxymethylphenylthio)benzylamine derivatives as PET serotonin transporter ligands. J Med Chem (2007) 0.85
Investigation of an F-18 oxytocin receptor selective ligand via PET imaging. Bioorg Med Chem Lett (2013) 0.85
Compartmental modeling of 11C-HOMADAM binding to the serotonin transporter in the healthy human brain. J Nucl Med (2008) 0.85
Carbon-11 HOMADAM: a novel PET radiotracer for imaging serotonin transporters. Nucl Med Biol (2005) 0.85
Initial experience with the radiotracer anti-1-amino-3-[18F]Fluorocyclobutane-1-carboxylic acid (anti-[ 18F]FACBC) with PET in renal carcinoma. Mol Imaging Biol (2009) 0.84
Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions. Mol Imaging Biol (2013) 0.84
Simultaneous measurement of extracellular dopamine and dopamine transporter occupancy by cocaine analogs in squirrel monkeys. Synapse (2012) 0.84
Synthesis and evaluation of 2-amino-4-[(18)F]fluoro-2-methylbutanoic acid (FAMB): relationship of amino acid transport to tumor imaging properties of branched fluorinated amino acids. Nucl Med Biol (2003) 0.84